Lymphoma, Non-Hodgkin  >>  Gazyva (obinutuzumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
GOYA, NCT01287741 / 2010-024194-39: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma

Checkmark From GOYA trial in 1L DLBCL at ASH 2016
Dec 2016 - Dec 2016: From GOYA trial in 1L DLBCL at ASH 2016
Terminated
3
1418
Canada, Japan, US, Europe, RoW
Rituximab, MabThera, Rituxan, Obinutuzumab, GA101, RO5072759, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Hoffmann-La Roche, Fondazione Italiana Linfomi ONLUS
Diffuse Large B-Cell Lymphoma
04/16
01/18
GAINED, NCT01659099 / 2011-005851-15: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

Terminated
3
671
Europe
GA101, obinutuzumab, Gazivaro, Rituximab, Mabthera, Doxorubicin, Cyclophosphamide, Prednisone, Bleomycin, Vindesin, Vincristine
The Lymphoma Academic Research Organisation, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma CD20 Positive
08/16
12/17

Download Options